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Apoptosis Induction by SAHA in Cutaneous
T-Cell Lymphoma Cells Is Related to Downregulation
of c-FLIP and Enhanced TRAIL Signaling
Nadya Al-Yacoub1, Lothar F. Fecker1, Markus Mo¨bs1, Michael Plo¨tz1, Frank K. Braun1,
Wolfram Sterry1 and Ju¨rgen Eberle1
Suberoylanilide hydroxamic acid (SAHA) has been approved for the treatment of cutaneous T-cell lymphoma
(CTCL), but its mode of action remained largely elusive. As shown here in four CTCL cell lines, loss of cell
viability correlated with significant time- and dose-dependent induction of apoptosis, whereas cytotoxicity was
less pronounced. Both extrinsic and intrinsic apoptosis pathways were activated, as seen by processing of initiator
caspases 8 and 9, loss of mitochondrial membrane potential, and cytochrome c release. Characteristically,
antiapoptotic mediators such as Mcl-1, XIAP, survivin, and c-FLIP were downregulated. Consistent with its
critical function, c-FLIP overexpression resulted in a significant decrease of SAHA-mediated apoptosis.
Enhanced sensitivity to TRAIL (TNF-related apoptosis-inducing ligand) and enhanced TRAIL signaling was seen
in CTCL cell lines with high sensitivity, whereas cell lines with moderate response were characterized by
downregulation of TRAIL-R2 and weaker TRAIL expression. Comparable proapoptotic responses to SAHA and
to the combination with TRAIL were seen in ex vivo tumor T cells of CTCL patients. Thus, activation of extrinsic
apoptosis pathways, related to c-FLIP downregulation and enhanced TRAIL signaling, appeared as characteristic
for CTCL cell responsiveness to SAHA. An improved understanding of the pathways may facilitate its targeted
use and the selection of suitable combinations.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is described as a distinct
group of extranodal non-Hodgkin lymphomas with primary
appearance in skin. It is characterized by clonal proliferation
of malignant CD4þ skin-homing lymphocytes. Most com-
mon subtypes are mycosis fungoides, Se´zary syndrome (SzS),
and CD30(þ ) lymphoproliferative disorders (Willemze et al.,
2005). Current therapies comprise skin-directed or systemic
treatment, depending on the stage of the disease. Particularly
in progressed disease, treatment becomes difficult and
chemotherapy non-efficient (Mestel et al., 2009). Thus, new
therapeutic strategies are considered, which may also include
histone deacetylase inhibitors (HDACi).
Therapy resistance of tumor cells is frequently explained in
terms of defects in apoptosis signaling (Eberle et al., 2007).
Extrinsic proapoptotic pathways are initiated by death ligands
such as TNF-a, CD95L/FasL, and TRAIL (TNF-related
apoptosis-inducing ligand), and they critically contribute to
an antitumor immune response, as well as to the autoregula-
tion of lymphocytes. Their binding to death receptors such
as TNF-R1, CD95/Fas, TRAIL-R1/DR4, and TRAIL-R2/DR5
results in the formation of a death-inducing signaling complex,
where proapoptotic initiator caspases (8 and 10) are activated
(Krammer et al., 2007). Caspase 8 is negatively regulated
by c-FLIP (cellular FLICE-inhibitory protein), which binds to
the death-inducing signaling complex in a competitive manner
(Irmler et al., 1997).
On the other hand, intrinsic apoptosis pathways are based
on the release of mitochondrial factors such as cytochrome c,
which triggers the activation of initiator caspase 9. Bcl-2
family members are critically involved in the regulation of
this step (Reed, 2008). Initiator caspases (8, 9, and 10) may
cleave and activate effector caspases such as caspase 3,
which themselves have a number of death substrate targets.
The final result is a complete reprogramming of the cell with
DNA fragmentation and formation of apoptotic bodies (Riedl
and Shi, 2004).
Defective regulation of apoptosis has been considered as a
main cause for accumulation of clonal T cells (Zhang et al.,
2003), and it was related to an impaired expression of
CD95 (Contassot et al., 2008; Wu et al., 2009), as well as
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constitutive activation of NF-kB (Sors et al., 2006). In
previous studies, we have shown the pronounced resistance
of CTCL cells to TRAIL-induced apoptosis, which was
particularly related to the upregulation of c-FLIP (Braun
et al., 2007, 2010).
HDACi have been developed in recent years as effective
anticancer agents (Luu et al., 2008; Bots and Johnstone,
2009). Both histone-related effects, which may result in
unfolded chromatin structure and in changes in gene
expression, as well as regulation of non-histone proteins,
such as p53, a-tubulin, heat-shock protein 90, and chemo-
kine receptors such as CXCR4, have been described (Bolden
et al., 2006; Siegel et al., 2009; Stamatopoulos et al., 2010).
The response of cancer cells may enclose cell cycle arrest,
cell differentiation, autophagy, apoptosis, and impaired
T-cell receptor signaling, whereas normal cells are less
affected (Lane and Chabner, 2009; Wozniak et al., 2010).
Some HDACi are in preclinical and early clinical studies
(Lane and Chabner, 2009; Stimson et al., 2009), and the pan-
HDACi SAHA (suberoylanilide hydroxamic acid; Vorinostat,
Zolinza) has recently been approved by the US Food and
Drug Administration for the treatment of CTCL (Khan and La
Thangue, 2008). In the present study, we addressed its mode
of action and induction of apoptosis in CTCL cell lines and in
ex vivo tumor T cells.
RESULTS
Decreased cell viability in correlation with induced apoptosis
When investigating the effects of SAHA on CTCL cells, dose-
dependent induction of apoptosis was seen in four cell lines
reaching 35–80% of apoptosis with 10 mM SAHA at 48 hours.
Cell lines HH and Hut-78 were most sensitive, whereas MyLa
and SeAx showed a somewhat reduced response (Figure 1a).
Time kinetic analyses showed that apoptosis was induced in
HH already at 24 hours, whereas the response of MyLa was
somewhat delayed and started at 48 hours (Figure 1c).
No significant increase of cytotoxicity was seen at
moderate concentrations, whereas at conditions of 80%
apoptosis (HuT-78, 48 hours, 10mM) cytotoxicity was also
strongly enhanced (Figure 1b). The response to even
moderate concentrations of 2.5 mM SAHA at 48 hours
corresponded to almost 70% sub-G1 cells (apoptotic) for
HH and HuT-78 and to 12–14% for MyLa and SeAx (Figure
1d). As a result of induced apoptosis, cell proliferation was
strongly decreased in a dose- and time-dependent manner,
reaching a reduction of 60% in HH and MyLa (10 mM,
48hours), as determined by water-soluble tetrazolium-1 assay
(Figure 1e). Thus, CTCL cells revealed general sensitivity to
SAHA-induced apoptosis.
Activation of extrinsic and intrinsic apoptosis pathways
For unraveling the signaling pathways triggered by SAHA in
CTCL cells, caspase processing was investigated. Complete
activation of caspases was evident in highly sensitive HH and
HuT-78 already at 2.5 mM and 24 hours, whereas less sensitive
MyLa and SeAx needed 10 mM or 48 hours. Characteristic
cleavage products were seen for both the extrinsic initiator
caspase 8 (43, 41, and 18 kDa) and for the intrinsic initiator
caspase 9 (37 and 35 kDa). The main effector caspase 3 was
processed to its cleavage products of 17 and 15 kDa. In
addition, loss of the caspase proforms was evident at 48 hours
(Figure 2a and b). Thus, at all conditions, we obtained a tight
correlation of apoptosis induction and caspase processing,
indicative for its decisive role. This was further proven by
preincubation with the pan-caspase inhibitor QVD-OPH,
which significantly blocked apoptosis by SAHA to base or
low levels in both cell lines (Figure 2c). Abrogated apoptosis
by QVD-OPH resulted in almost complete protection of cell
survival, as shown by calcein assay (Figure 2d), and also
cytotoxicity was not enhanced (Figure 2e).
Decreased mitochondrial membrane potential (Dcm), a
hallmark in intrinsic apoptosis pathways, was characteristic
for SAHA-treated cells at 48 hours. SAHA (1 mM) decreased
Dcm in 79% of HH and in 15% of MyLa cells, as compared
with 24% and 9% in the controls, respectively (Figure 2f).
In parallel with delayed apoptosis in MyLa (Figure 1c),
no decrease of Dcm was seen at 24 hours (Figure 2f). The
numbers of cells with loss of Dcm correlated with
the percentage of apoptosis (Figure 1a). Further supporting
the activation of mitochondrial apoptosis pathways, signifi-
cant mitochondrial release of cytochrome c was seen in
MyLa and HH at 24 hours of SAHA treatment (Figure 2g).
Thus, apoptosis induction by SAHA in CTCL cells appeared
as related to the activation of both extrinsic and intrinsic
apoptosis pathways.
Characteristic downregulation of c-FLIP by SAHA
For a better understanding of apoptosis induction, the
expression of apoptosis regulators was monitored in SAHA-
treated CTCL cells. Pro- and antiapoptotic Bcl-2 family
members, c-IAPs (XIAP, survivin), and the caspase 8/10
inhibitor c-FLIP were included. As for Bcl-2 family members,
downregulation of antiapoptotic Mcl-1 became evident
(Figure 3a), which may support activation of the mitochon-
drial pathway, whereas Bcl-2 and Bax did not show
reproducible changes (data not shown). Strikingly, also some
proapoptotic Bcl-2 family members were strongly down-
regulated, such as the BH3-only proteins Noxa and Puma,
which appeared as a kind of counter-regulation in apoptosis
(Figure 3a). Indicative for a release of effector caspases,
remarkable downregulation of survivin and XIAP was seen
in response to SAHA in CTCL cell lines. Of particular
interest was c-FLIP, which exerts significant functions in
apoptosis deficiency in CTCL (Braun et al., 2007). Indeed,
10 mM SAHA resulted in almost complete downregulation
of both c-FLIP isoforms (FLIPL and FLIPS) in all CTCL cell
lines at 24 hours. Downregulation was also seen with
moderate concentrations of SAHA in HH, SeAx, and
HuT-78 (Figure 3a–c).
The role of c-FLIP was further investigated by transduction
of MyLa cells with a retrovirus for FLIPL overexpression.
Transduction efficiencies were at 90%, as determined by flow
cytometry for the co-expressed EGFP enhanced green
fluorescent protein (Figure 3d, inset), and overexpress-
ion of FLIPL was proven by western blotting (Figure 3e).
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Figure 1. Proapoptotic effects of suberoylanilide hydroxamic acid (SAHA) on cutaneous T-cell lymphoma (CTCL) cells. (a, b) CTCL cell lines were treated
for 48 hours with increasing concentrations of SAHA. Induction of apoptosis ((a) flow cytometry after propidium iodide (PI) staining) and of cytotoxicity ((b)
lactate dehydrogenase (LDH) release) is shown. For cytotoxicity, triton X-100-treated cells served as positive controls (T¼ 100%). (c) Time kinetic analyses
of apoptosis (relative values, apoptosis ELISA) and cytotoxicity are shown for HH (1, 10 mM SAHA) and MyLa (2.5, 10 mM). (d) Representative histograms of
sub-G1 apoptotic cell populations (sG1) are shown in response to SAHA (2.5 mM, 48 hours), as compared with controls (% of sub-G1 cells indicated).
(e) Cell proliferation was determined by the water-soluble tetrazolium (WST)-1 assay in HH and MyLa at 24 and at 48 hours of treatment with increasing
concentrations of SAHA (C, nontreated controls¼ 100%). Statistical significance of differences is indicated (*Po0.05, Student’s t-test).
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Exogenous FLIPL expression could not be downregulated by
SAHA, likely indicating a regulation of c-FLIP at the
transcriptional level rather than protein stability. Upon FLIPL
overexpression, SAHA-induced apoptosis was significantly
diminished, as compared with mock-transduced controls,
thus proving a critical contribution of c-FLIP downregulation
in SAHA-mediated effects (Figure 3d).
Enhanced TRAIL signaling in highly sensitive CTCL cells
With regard to the activation of extrinsic proapoptotic
pathways (caspase 8), death ligands and their receptors
appear to be of particular interest. We identified a striking
upregulation of TRAIL surface expression by SAHA in HH
and HuT-78 cells already at moderate concentrations (0.5 or
2.5 mM). In contrast, TRAIL surface expression in less sensitive
cells was weaker (MyLa) or not significant (SeAx), and it was
not induced by SAHA (Figure 4a and b).
Interestingly, TRAIL receptor 2/DR5 was consistently
downregulated at its protein level in less sensitive MyLa
and SeAx, already at moderate concentrations. In contrast, it
remained a rather stable expression in HH and HuT-78 and
was even upregulated at a concentration of 10 mM (Figure 4c).
A comparable picture was seen for DR5 at the surface
expression level, namely significant downregulation in MyLa
and SeAx, whereas it revealed a stable expression in HH and
HuT-78 (Figure 4d). Thus, high sensitivity of CTCL cells
correlated with enhanced TRAIL signaling in response to
SAHA, whereas the diminished response was associated with
downregulated TRAIL signaling.
Sensitization of CTCL cells for TRAIL-induced apoptosis
The effects of activated TRAIL signaling may be neutralized
by resistance to TRAIL-induced apoptosis, which we had
reported previously for CTCL cells (Braun et al., 2007).
However, SAHA mediated a significant enhancement of
TRAIL-induced apoptosis in CTCL cells. Whereas in HH
0.3 mM SAHAþTRAIL already resulted in 23% apoptotic
cells at 48 hours, MyLa cells needed higher concentrations
of SAHA (2.5 mM) for an additive enhancement of
apoptosis (Figure 5a). Enhanced TRAIL-induced apoptosis
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Figure 2. Activation of caspases and mitochondria. (a, b) Processing of caspases (Csp) 8, 9, and 3 in response to suberoylanilide hydroxamic acid (SAHA; 1, 2.5,
10mM; 24, 48hours) is demonstrated in cutaneous T-cell lymphoma (CTCL) cells by western blotting (loading control: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), 30mg per lane). Caspase activation is seen by specific cleavage products ( ). (c–e) HH and MyLa were pretreated for 1 hour with the pan-caspase
inhibitor QVD-OPH (QVD) before SAHA treatment started (2.5mM). Anti-CD95 agonistic antibody (CH-11) was used as control for caspase inhibition by
QVD-OPH. After 48hours of treatment, (c) apoptosis (sub-G1 cells), (d) cell survival (calcein staining), and (e) cytotoxicity (lactate dehydrogenase (LDH) release)
were determined. (f) Mitochondrial membrane potential (Dcm) was determined by TMRM
þ staining in SAHA-treated HH and MyLa (1mM, 24 or 48 hours).
Representative histograms of treated cells (gray) are shown in overlays with nontreated controls (white graphs). Bars indicate populations with decreased Dcm, and
the % of cells with low Dcm is given for 48hours (nontreated/treated). (g) Cytochrome c release in response to SAHA treatment (24hours) is shown in MyLa and
HH (Cyto, cytosolic, and Mito, mitochondrial extracts; GAPDH as loading control). Experiments were conducted at least twice, revealing comparable results.
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was associated with reduced cell viability (Figure 5a), and it
coincided with enhanced activation of initiator caspase 8
and effector caspase 3 in HH cells (Figure 5b).
SAHA, however, did not appear as an unspecific activator
of general apoptosis programs as shown for combinations
with bortezomib and methotrexate. Whereas a positive
combination effect was seen with bortezomib in agreement
with previous findings (Heider et al., 2009), SAHA did not
enhance apoptosis induced by methotrexate in MyLa and did
not overcome methotrexate resistance in HH (Figure 5c).
Also, cytotoxicity was not significantly enhanced in the
combination (data not shown).
Correlation of in vitro and ex vivo data
For assessing the significance of the cell line data for the
clinical situation, CD4-selected T cells of ten SzS patients and
four healthy donors were investigated ex vivo. High tumor
cell count in patient samples was assured. Thus, enrichment
of T cells by the CD4 selection was over 95%, as proven by
CD3 and CD4. Furthermore, the proportion of tumor cells
was over 88% within the T-cell subpopulations (CD3+,
CD4+), as proven by expression of the tumor-specific TCRb
variable chain, which had been determined for each patient
(Steininger et al., 2011). High tumor cell counts were also
underlined by low expression of CD7 and CD26 or by loss of
p53 (Table 1). Apoptosis was significantly enhanced by
SAHA (1 mM, 48 hours) in 8 of 10 samples of SzS patients,
whereas cytotoxicity was not affected (Figure 6a).
The concentration dependency was determined in pre-
parations of four SzS patients and four healthy donors.
Apoptotic rates strongly increased in a dose-dependent
manner in the patient samples, reaching up to 45–70% of
apoptotic cells at 10 mM (48 hours). In comparison, the
response of control T cells was much reduced with a
maximum of only 10% apoptosis (Figure 6b and c). In
parallel with apoptosis, enhancement of cytotoxicity
was seen at higher concentrations, and enhanced cell
death resulted in a marked decrease of cell viability
(10 vs. 90%; Figure 6c). Mean induction of apoptosis by
SAHA (1 mM, 48 hours) was significantly higher in patient
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Figure 3. Downregulation of apoptosis regulators. (a) Expression of Bcl-2 family members (Mcl-1, Noxa, Puma) and caspase inhibitors (survivin, XIAP, c-FLIP) is
shown in HH and MyLa (western blotting) in response to suberoylanilide hydroxamic acid (SAHA) treatment (2.5, 10mM; 24 and 48hours), and (b) expression of
c-FLIP and XIAP is shown in SeAx and HuT-78 at 24hours (loading control: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 30mg per lane). (c) Comparable
results were obtained with another set of independent extracts. Expression was quantified by densitometry, and mean values of each two independent experiments
(2.5, 10mM SAHA) are shown. Expression in nontreated controls was set to 100%. (d) Apoptotic response to SAHA (sub-G1 cells; 0.5–5mM, 48hours) is shown in
MyLa cells that had been stably transduced with a FLIPL retrovirus, as compared with mock-transduced cells. Mean values±SDs of a representative experiment are
shown (two independent with triplicates). Statistical significance of reduced apoptosis in FLIPL-transduced cells is indicated (*Po0.005). The proportion of
transduced cells (almost 100%) is displayed by green fluorescent protein (GFP) expression, as determined by flow cytometry (shift to the right, insets). (e) FLIPL
overexpression is demonstrated by western blotting, as compared with mock-transduced controls (loading control, GAPDH, 30mg per lane).
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tumor T cells (17±7%) as compared with T cells of controls
(4.7±1.2%; Po0.05). As in cell lines, combinations of
SAHA and TRAIL resulted in enhanced apoptosis also in
tumor T cells, and the effects were less pronounced in normal
T cells (Figure 6d). Thus, a significant proportion of tumor
T cells were strongly responsive to SAHA, and the proapop-
totic effects could be further enhanced by combination
with TRAIL.
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Figure 4. Regulation of TNF-related apoptosis-inducing ligand (TRAIL) and DR5. (a) Surface expression of TRAIL (flow cytometry) is shown in cutaneous T-cell
lymphoma (CTCL) cells in response to suberoylanilide hydroxamic acid (SAHA; 24 and 48 hours; 0.5–5 mM; open graphs). Controls: nontreated (0mM) and IgG
staining (filled graphs in overlays). (b) Mean values and SDs for TRAIL expression in response to SAHA (2.5 mM, 24 hours) are given of each three independent
experiments. (c) Expression of DR5 is shown in CTCL cells in response to SAHA (1, 2.5, 10mM; western blotting, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as loading control, 40mg per lane). Two experiments with independent extracts showed comparable results. (d) Surface expression of DR5 (flow
cytometry) in response to SAHA (24 hours; open graphs). Controls: nontreated (0 mM) and IgG staining (filled graphs in overlays). (e) Mean values and SDs for
DR5 expression in response to SAHA (2.5 mM, 24 hours) are given of each three independent experiments.
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DISCUSSION
HDACi have shown efficacy in hematological and solid
tumors as single agents or in combinations (Luu et al., 2008;
Bots and Johnstone, 2009; Wozniak et al., 2010). Moreover,
SAHA (Vorinostat) has proven antitumor activity in a broad
range of hematological malignancies (Stimson et al., 2009;
Stamatopoulos et al., 2010) and was recently approved by the
US Food and Drug Administration for the treatment of CTCL
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Figure 5. Enhanced TNF-related apoptosis-inducing ligand (TRAIL)–induced apoptosis in combination with suberoylanilide hydroxamic acid (SAHA).
(a) Combination effects of SAHA and TRAIL are shown by induced apoptosis (sub-G1 cells, HH, MyLa) and by decreased cell viability (HH, calcein staining).
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in HH cells in response to combination treatment was determined by western blotting (30mg per lane, glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as control). Caspase activation is seen by specific cleavage products (indicated by scissors). Another set of experiments with independent extracts yielded
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Table 1. Characteristics of patient tumor T cells
No. Age (years) Sex WBC Treatment CD3+ CD4+ 1 Vbx
+ 2 CD7 3 CD26 3 p53 4
1 63 F 15.3 ECP — 93 96 97 —
2 72 M 11.5 PUVA, ECP, IFN, Ac — 96 92 58 —
3 60 M 34.8 IFN, ECP, Al 97 99 33 95 —
4 89 M 7.8 PUVA, ECP — 88 97 97 —
5 73 M 22.2 UV, ECP 98 99 — — 100
6 64 F 30.1 IFN, ECP, Ch+Pr, PUVA, MTX, Cyc, SAHA+Bex — — 23 94 —
7 59 M 12.6 IFN+ECP, Ch+Pr, SAHA+Bex — 97 18 91 —
8 72 F 8.1 ECP, PUVA, IFN — 94 — — 97
9 70 F — ECP, PUVA, IFN, Bex, Ch+Pr 99 — 77 96 —
10 64 F 19.4 ECP, IFN, MTX, Ac, Bex — 98 16 96 —
Abbreviations: Ac, acitretin; Al, alitretinoin; Bex, bexarotene; Ch, chlorambucil; Cyc, cyclophosphamide; ECP, extracorporeal photopheresis; F, female;
IFN, IFN-a; M, male; MTX, methotrexate; Pr, prednisone; PUVA, psolaren+long-wave UV irradiation; UV, UV light irradiation (wave length not specified);
WBC, white blood cell count per nl.
1Percent of CD3+/CD4+ cells after CD4+ selection.
2Percent of Vbx
+ cells in CD4+/CD3+ populations.
3Percent of CD7- and CD26-negative cells, respectively, in CD3+/CD4+/Vbx+ cell populations or in CD3+/CD4+ cell populations (patients 6 and 9).
4Percent of cells with lost p53, as determined by fluorescence in situ hybridization analysis in Vbx-sorted cells (Steininger et al, 2011).
‘‘–’’, Not done or not applicable.
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Figure 6. Effects of suberoylanilide hydroxamic acid (SAHA) in tumor T cells. (a) Isolated tumor T cells (CD4-selected) of ten Se´zary syndrome patients (P1–P10)
were treated with SAHA (1 mM, 48 hours), and apoptosis (sub-G1 cells) and cytotoxicity were determined. (b) Dose-dependent induction of apoptosis (sub-G1
cells, 48 hours) was determined in cells of patients (P1, P2, P4) and healthy donors (HD 1–3). (c) Dose-dependent induction of apoptosis (sub-G1 cells) was
compared with cytotoxicity (Cytotox) and related to decreased cell proliferation in P10 and HD4. For cytotoxicity, triton X-100-treated cells served as positive
control (T¼ 100%). (d) Apoptosis was determined in response to SAHA (2.5 mM, 48 hours) ±TRAIL (TNF-related apoptosis-inducing ligand; 20 ngml1, last
24 hours). (a–d) Mean values±SDs of triplicates.
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(Khan and La Thangue, 2008). Induction of apoptosis,
terminal differentiation, and growth arrest have been related
to SAHA in tumor cells, whereas normal cells remained
largely unaffected (Lane and Chabner, 2009; Dickinson et al.,
2010). In CTCL cells, apoptosis induction accompanied by
caspase 3 activation has been reported (Zhang et al., 2005;
Fantin et al., 2008; Heider et al., 2009); however, the
pathways remained largely elusive. The present study
demonstrates the activation of both extrinsic (caspase 8) and
intrinsic (caspase 9) apoptosis pathways. Apoptosis appeared
as the major effect and was correlated to decreased cell
survival, whereas cytotoxicity remained at a lower level.
Mitochondrial activation after SAHA treatment was evident
by the decrease of the mitochondrial membrane potential and
by cytochrome c release, similar to findings in hepatocellular
carcinoma and Hodgkin lymphoma cells (Carlisi et al., 2009;
Buglio and Younes, 2010). Mitochondrial apoptosis pathways
are promoted by proapoptotic Bcl-2 family members,
frequently regulated in the course of apoptosis (Youle and
Strasser, 2008). Thus, Bax and Bak were upregulated by
HDACi in melanoma cells (Zhang et al., 2004), and
upregulation of the BH3-only proteins Noxa, Puma, and
Bim appeared in breast cancer and leukemic cells (Inoue
et al., 2007; Shankar et al., 2009). In clear contrast, no
increase of proapoptotic Bcl-2 family members was seen in
CTCL cells; rather, Noxa and Puma were strongly down-
regulated in a kind of counter-regulatory response. Such
counter-regulations are not unusual in regulation of apoptosis
and may allow a cell to give an adequate and differentiated
response to proapoptotic stimuli. Thus, downregulation of
Noxa and Puma was also reported in myeloma cells by the
HDACi trichostatin A (Fandy and Srivastava, 2006). These
proteins may be considered as additional targets for enhan-
cing SAHA effects in combination therapy.
With regard to antiapoptotic Bcl-2 family members, Bcl-2,
Bcl-xL, and Mcl-1 had been reported as downregulated by
HDACi in small-cell lung cancer, breast cancer, and
leukemia cells, respectively (Rosato et al., 2006; Mitchell
et al., 2007; Crisanti et al., 2009). In CTCL cells, we show the
downregulation of Mcl-1, which may have a contributory
role in the activation of intrinsic apoptosis pathways.
Caspase inhibitors such as c-IAPs have additional crucial
roles in preventing apoptosis (Dubrez-Daloz et al., 2008).
Indeed, XIAP and survivin were expressed in CTCL cells and
were diminished in response to SAHA, likely indicating their
role in opening the caspase cascade. Downregulation of
these proteins was also seen in neuroblastoma cells
(Muhlethaler-Mottet et al., 2008).
Of particular interest appeared the caspase 8/10 inhibitor
c-FLIP, which exerts a predominant role in resistance of CTCL
cells to extrinsic apoptosis signals (Braun et al., 2007, 2010).
Characteristically, the isoforms FLIPL and FLIPS were strongly
downregulated by SAHA in CTCL cells. The critical role of
FLIPL was evident, as its overexpression strongly diminished
SAHA-mediated apoptosis. FLIP exerts an essential role for
CTCL cell survival, as shown by its shRNA-mediated down-
regulation, which was strongly associated with induced
apoptosis (Braun et al., 2012). Downregulation of c-FLIP by
HDACi was also reported in lymphoid malignant cells and
in chronic lymphocytic leukemia cells (Aron et al., 2003;
Sanda et al., 2007). As c-FLIP is a NF-kB target (Micheau
et al., 2001) and NF-kB exerts critical functions for CTCL
survival (Sors et al., 2006), c-FLIP downregulation by SAHA
may indicate NF-kB inhibition. Indeed, HDACi-mediated
inhibition of NF-kB has been reported in non-small-cell lung
cancer cells and in pancreatic cancer cells (Imre et al., 2006;
Lehmann et al., 2009).
Thus, SAHA treatment resulted in downregulation of
multiple apoptosis regulators in CTCL cells. As causes of
protein downregulation, proteasomal degradation may be
ruled out, as the proteasomal pathway may be suppressed by
HDACi (Khan et al., 2010). Caspase-mediated processing
may be considered because of strong caspase 3 activation in
CTCL cells. Caspase-mediated degradation of Mcl-1 (Wardle
et al., 2011), XIAP (Muhlethaler-Mottet et al., 2008), and
Puma (Hadji et al., 2010) has been reported in neutrophils,
neuroblastoma cells, and Jurkat cells, respectively. Never-
theless, gene regulation appears as a major target of HDACi
activity (Dickinson et al., 2010). Thus, the delayed response
of CTCL cells to SAHA (24 hours) indicates time-consuming
mechanisms related to altered gene expression. In addition,
retrovirus-mediated overexpression of c-FLIP was not a target
of SAHA-mediated downregulation.
Of particular note, TRAIL signaling appeared as signifi-
cantly contributing to SAHA effects. Thus, caspase activation
and downregulation of c-FLIP and XIAP were found in all
four cell lines, suggesting the principal importance of these
regulations. Furthermore, upregulation of TRAIL was seen
in highly responsive cells (HH and HuT-78), whereas less
sensitive cells showed only weak TRAIL expression. With
regard to the TRAIL receptor DR5, it remained a rather
stable expression in highly sensitive cells but was down-
regulated in the less responsive cells. These differences
might be of help for selecting good responders in clinical
settings.
TRAIL represents a promising anticancer agent (Ashkenazi
et al., 2008); however, CTCL cells had been characterized by
pronounced TRAIL resistance as related to high c-FLIP
expression (Braun et al., 2007, 2010). Strategies for over-
coming TRAIL resistance in CTCL thus appear of particular
interest. It is noteworthy that SAHA significantly enhanced
TRAIL sensitivity of CTCL cells. Enhanced TRAIL sensitivity in
response to SAHA was also seen in breast cancer and
leukemic T cells (Shankar et al., 2009; Morales et al., 2010).
It may support the self-regulatory control of T lymphocytes
based on death ligand signaling (Janssen et al., 2005).
Furthermore, recovered TRAIL sensitivity may allow apopto-
sis induction in CTCL cells in relation to SAHA-mediated
TRAIL upregulation. Finally, recovered TRAIL sensitivity may
facilitate TRAIL-based therapeutic approaches in combina-
tion treatments.
The cell line data of the present paper were supported by
the response of ex vivo tumor T cells of SzS patients.
Largely comparable with the cell lines, ex vivo cells
revealed significant responsiveness to SAHA, as well as an
enhancement of their TRAIL sensitivity. Thus, because of a
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comparable response of all CTCL cell lines regarded as
representative for CTCL, as well as because of a compar-
able response of tumor T cells ex vivo, we may largely
exclude a cell line effect. However, the proapoptotic
effects of SAHA were not restricted to tumor T cells, and it
has also been reported that SAHA may induce lymphope-
nia in treated patients (Luu et al., 2008). Nevertheless, we
show here that normal T cells from healthy donors were
much less sensitive to SAHA-induced apoptosis than
malignant cells, which is in line with previously published
data (Zhang et al., 2005).
In summary, SAHA exerted strong antitumor effects on
CTCL cells related to induction of apoptosis via extrinsic and
intrinsic pathways. Downregulation of c-FLIP, c-IAPs, and
Mcl-1, as well as enhanced TRAIL signaling, appeared as
most characteristic. With regard to the role of death
ligand–mediated lymphocyte autoregulation, TRAIL pathways
deserve particular attention. The detailed unraveling of
SAHA-mediated effects will be helpful for a targeted use in
CTCL and for further selection of suitable combination
partners.
MATERIALS AND METHODS
Cell culture and viral vectors
Four CTCL cell lines have been used: MyLa derived from a plaque
biopsy of a patient with mycosis fungoides (Kaltoft et al., 1992), SeAx
(Kaltoft et al., 1987) and HuT-78 (Gootenberg et al., 1981) derived
from PBMCs of patients with SzS, and HH (CRL-2105, ATCC,
Manassas, VA) derived from peripheral blood of a patient with
aggressive CTCL (Starkebaum et al., 1991). Cells were grown at 37 1C
and 5% CO2 in RPMI 1640 medium supplemented with L-glutamine,
10% fetal calf serum, and antibiotics (Biochrom, Berlin, Germany).
As death agonists, killerTRAIL (Alexis, Gruenberg, Germany;
10–20ngml1) and anti-CD95 antibody (CH-11; Beckman Coulter,
Krefeld, Germany; 50 ngml1) were applied. SAHA (Vorinostat) was
provided by Merck (MSD, Whitehouse Station, NJ) and was
dissolved in DMSO at 20mM. For caspase inhibition, cells were
pre-incubated with the pan-caspase inhibitor QVD-Oph (R&D
Systems, Minneapolis, MN), which was used at 50 mM for HH and
at 10mM for MyLa, respectively. Bortezomib (Millennium Pharma-
ceuticals, Cambridge, MA) was used at concentrations of 2.5–5 nM;
methotrexate (Teva, Ulm, Germany) was used at concentrations of
50–300mM.
For overexpression of c-FLIPL, a retroviral vector was kindly
provided by Professor M. Leverkus (Mannheim, Germany). This also
encodes for a zeocin resistance gene and for green fluorescent
protein, as described previously (Geserick et al., 2008). MyLa cells
stably transduced with a retrovirus by means of polybrene for
c-FLIP(subscribe)L expression have been described previously (Braun
et al., 2012). Selection with zeocin (ant-zn-1, InvivoGen, San Diego,
CA) was performed in increasing doses (100–500 mgml1). Trans-
duction efficiencies were determined by flow cytometric analysis for
green fluorescent protein.
Cell death and viability assays
Percentages of apoptotic, hypodiploid cells were determined by
flow cytometry after propidium iodide DNA staining. Cells were
harvested by centrifugation, washed with cold phosphate-
buffered saline (PBS), lysed, and stained for 1 hour in a hypotonic
solution containing propidium iodide (40 mgml1), 0.1% sodium
citrate, and 0.1% triton X-100. The DNA content of nuclei was
determined by flow cytometry, using a FACSCalibur flow
cytometer and the CellQuest (BD Biosciences, Heidelberg,
Germany) or WinMDI software (Scripps Research Institute, La Jolla,
CA). Cytotoxicity was determined in parallel by a lactate dehydro-
genase release assay, according to protocols of the supplier (Roche
Diagnostics, Mannheim, Germany). As positive cytotoxicity control,
cells grown in parallel were lysed by treatment with 0.5% triton
X-100. For time kinetic analysis, relative apoptosis values were
determined with respect to nontreated controls by a highly sensitive
cell death detection ELISA (Roche Diagnostics).
Cell proliferation was quantified according to the cleavage of the
water-soluble tetrazolium by mitochondrial dehydrogenases in
metabolically active cells (Roche Diagnostics). Cells were seeded
at a density of 15,000 cells per 100 ml in 96-well plates, and
treatments were started after 24 hours. At the time of analysis, water-
soluble tetrazolium-1 reagent was added and absorbance was
determined at 450 nm in an ELISA reader. Data were reported as
percentage of nontreated controls. Cell viability was monitored
using the live-cell labeling dye calcein-AM. Briefly, 105 cells were
incubated with calcein (4 mM; eBioscience, Frankfurt, Germany) in
serum-free growth medium (60minutes, 37 1C). After PBS washing,
cell viability was determined by flow cytometry, comparing calcein-
stained (viable) and -unstained (dead) cells. Calcein staining data
were largely in parallel with those of Trypan blue staining (not
shown).
For determination of the mitochondrial membrane potential
(Dcm), the cationic fluorescent dye tetramethylrhodamine methyl
ester perchlorate (TMRMþ , T5428, Sigma) was used. Cells were
harvested, stained with TMRMþ (1 mM, 15minutes, 37 1C), washed
with cold PBS, and analyzed by flow cytometry.
Western blot analysis
Detailed protocols for protein extraction and western blot analysis
have been given previously (Eberle et al., 2003). For determination
of cytochrome c release from mitochondria, cellular fractions were
obtained using a mitochondria/cytosol fractionation kit (Promokine,
Heidelberg Germany).
The following antibodies were used: caspase-8 (9746, 1C12; Cell
Signaling, Danvers, MA; 1:1,000); caspase-9 (9502; Cell Signaling;
1:1,000); caspase-3 cleavage products (9661, Asp175; Cell Signal-
ing; 1:1,000); procaspase-3 (9662; Cell Signaling; 1:1,000); c-FLIP
(G-11, sc-5276; Santa Cruz, Heidelberg, Germany; 1:200); Bax (N-
20, sc-493; Santa Cruz; 1:200); Bcl-2 (sc-509; Santa Cruz; 1:200);
Mcl-1 (sc-12756; Santa Cruz; 1:200); Puma (1652-1; Epitomics,
Burlingame, CA; 1:1,000); Noxa (1437; ProSci, Poway, CA; 1:500);
survivin (D-8, sc-17779; Santa Cruz; 1:200); XIAP (2042; Cell
Signaling; 1:1,000); cytochrome c (Cell Signaling, 1:500); DR4
(8414; Abcam, Cambridge, MA; 1:500); DR5 (8416; Abcam; 1:500);
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 6C5, sc-
32233; Santa Cruz; 1:200). Two horseradish peroxidase (hrp)–la-
beled secondary antibodies were used: hrp-labeled goat anti-rabbit
Ig and goat anti-mouse Ig (Dako Cytomation, Hamburg, Germany;
1:5,000). The expression of Mcl-1, XIAP, and FLIPL was semiquanti-
tatively analyzed by the TINA program (Raytest, Straubenhardt,
Germany).
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TRAIL and TRAIL receptor surface expression
Cells were harvested by centrifugation and washed with cold PBS/
1% BSA. For TRAIL, cells were incubated with PE-conjugated TRAIL
antibody (RIK2, sc-56246 PE; Santa Cruz; 1:5) for 30minutes in PBS/
BSA in the dark, washed, and resuspended in PBS. For TRAIL-R2/
DR5, cells were incubated for 15minutes at 4 1C in PBS/1% BSA
with primary mouse monoclonal antibodies (clone HS 201, ALX-
804-298-100, Alexis, 1:100). After washing, cells were incubated
with a secondary anti-mouse IgG1 antibody (ALX 211-201-050,
1:100) in PBS/BSA for 30minutes at room temperature. After
washing, cells were resuspended in PBS. Surface expression of
TRAIL and DR5 was determined by flow cytometry. As a control for
TRAIL, a PE-labeled isotype IgG1 antibody was used (#555749; BD
Biosciences; 1:5); as a control for TRAIL receptors, mouse IgG1
(#278–010; Ancell, Bayport, MN; 1:100) was used.
Isolation, enrichment, and quantification of tumor T cells from
SzS patients
Peripheral blood mononuclear cells (PBMCs) from venous blood,
collected from SzS patients and from healthy donors, were isolated
using density gradient centrifugation with Ficoll-Paque (GE Health-
care Bio-Sciences, Uppsala, Sweden). CD4þ cells were selected
with anti-CD4 magnetic microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturers’ recommenda-
tions. Enrichment of T cells, usually over 95%, was proven by flow
cytometry with anti-CD3 and anti-CD4 antibodies.
For determination of the percentage of tumor cells, at first the
specific TCRb variable chain (Vbx), expressed on the tumor cells of
individual SzS patients, was identified by PCR and subsequent
sequence analysis as described recently (Steininger et al., 2011).
With these data, tumor cells in PBMC samples of SzS patients were
quantified by flow cytometry, using CD3, CD4 and the respective
Vb-specific antibody. In the samples used here, positivity for CD3
and CD4 (T cells) was linked in at least 88% of cells with the
expression of the identified tumor cell–specific Vbx. The neoplastic
phenotype was further investigated by determination of CD7 and
CD26, which were reported as frequently lost in circulating Se´zary
cells (Willemze et al., 2005). Alternatively, samples were character-
ized by fluorescence in situ hybridization analysis of Vbx-sorted cells
for genomic loss of p53, as described previously (Steininger et al.,
2011). Antibodies for CD3, CD4, CD7, and CD26 were from BD
Biosciences, and Vbx antibodies were from Beckman Coulter. The
study was approved by the Charite´; written, informed patient con-
sent was given and it was conducted according to the Declaration of
Helsinki Principles.
Statistical analysis
Experiments usually consisted of triplicate values, and experiments
were conducted 2–3 times. The significance of differences between
experimental variables was determined by Student’s t-test, and a
P-value o0.05 was considered as statistically significant.
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